Continuous Bioprocessing Reshapes Biopharmaceutical Manufacturing

The global biotechnology market is transforming healthcare, agriculture, food production, and industrial manufacturing through the application of living organisms, biological systems, and cellular processes. Biotechnology combines biology, chemistry, and engineering to develop products and technologies for drug discovery, genetic engineering, vaccine production, disease diagnosis, and crop improvement. Advances in DNA sequencing, tissue engineering, precision fermentation, and molecular diagnostics are supporting innovation across multiple industries and strengthening demand for biotechnology solutions.

The global biotechnology market size was valued at USD 1,650 billion in 2025 and is projected to grow from USD 1,875.56 billion in 2026 to USD 5,227.53 billion by 2034, registering a CAGR of 13.67% during the forecast period from 2026 to 2034. North America dominated the market with a 41.2% share in 2025.

For detailed market insights, growth forecasts, and competitive analysis, visit:https://straitsresearch.com/report/biotechnology-market

Market Drivers

Biopharmaceutical Development for Chronic and Genetic Diseases Drives Market

Chronic conditions and inherited disorders require targeted treatment approaches, supporting the use of biotechnology in developing therapeutic proteins, monoclonal antibodies, and gene-based medicines. Biopharmaceutical companies use recombinant DNA technology and cell-based production methods to develop treatments for conditions such as cancer, diabetes, and genetic disorders. These applications support research investment and the supply of biotechnology-based therapeutic products across healthcare markets. Continued development of biological treatments is strengthening demand for specialized research platforms and biomanufacturing capabilities.

Genetic Engineering Applications in Crop Improvement Drive Market

Agricultural challenges such as pest attacks, crop diseases, and environmental stress encourage the use of genetic engineering in crop development. Biotechnology enables researchers to introduce or modify specific plant traits to improve disease resistance, nutritional characteristics, and tolerance to unfavorable growing conditions. Genetically modified insect-resistant crops, for instance, help farmers manage particular pest-related losses and support agricultural productivity. These applications are encouraging investment in agricultural biotechnology and advanced crop research.

Biotechnology Applications in Vaccine and Therapeutic Development Drive Market

Biotechnology plays an important role in developing vaccines and treatments for infectious diseases through recombinant technologies and biological production methods. These approaches enable manufacturers to develop biological products using specialized cell cultures, engineered organisms, and molecular techniques. Demand for advanced vaccines and targeted therapies supports investment in research facilities, production infrastructure, and specialized laboratory technologies. This is strengthening the role of biotechnology across pharmaceutical development and public health applications.

Market Trends

Adoption of Continuous Bioprocessing for Biopharmaceutical Production

The need for consistent product quality, efficient resource utilization, and shorter production cycles is encouraging biopharmaceutical manufacturers to adopt continuous bioprocessing. This approach replaces separate batch operations with connected processing stages, supporting improved process control, reduced downtime, and manufacturing efficiency. The U.S. Food and Drug Administration supports continuous manufacturing through its Emerging Technology Program, which helps pharmaceutical companies implement advanced production technologies and address regulatory considerations.

Development of Precision Fermentation for Sustainable Industrial Biotechnology

The need for sustainable alternatives to conventional chemical and agricultural production is encouraging biotechnology companies to develop precision fermentation platforms. These systems use engineered microorganisms to produce specific ingredients, including proteins, enzymes, and specialty compounds. The U.S. Food and Drug Administration maintains a regulatory consultation inventory that includes food ingredients produced through precision fermentation, demonstrating the application of this technology in commercial food production.

Market Challenges

The report does not provide a dedicated market restraints or challenges analysis. It identifies regulatory compliance, manufacturing capabilities, and advanced research requirements as important considerations across biotechnology applications. These factors can influence investment decisions, production processes, and the commercialization of biotechnology products.

Market Segmentation

The biotechnology market is segmented by technology and application. By technology, the market includes nanobiotechnology, tissue engineering and regeneration, DNA sequencing, cell-based assays, fermentation, PCR technology, chromatography, and others. DNA sequencing dominated with a 17.4% share in 2025, supported by its applications in genetic research, disease diagnosis, personalized medicine, and genomic analysis. Nanobiotechnology is projected to grow at a CAGR of 16.7% during the forecast period, driven by applications in targeted drug delivery, medical diagnostics, biosensors, and advanced biomaterials. By application, the market includes human health, food and agriculture, natural resources and environment, industrial processing, bioinformatics, and others. Human health dominated with a 48.6% share in 2025, owing to the use of biotechnology in drug development, disease diagnosis, vaccine production, and personalized healthcare. Bioinformatics is projected to grow at a CAGR of 17.8% during the forecast period, fueled by the need for computational tools to analyze complex biological data, interpret genomic information, and support drug discovery.

Regional Insights

North America dominated the biotechnology market with a 41.2% share in 2025. The region benefits from established pharmaceutical research, biomanufacturing infrastructure, and investment in advanced biological technologies. In the U.S., Genentech's approximately USD 2 billion investment in a new manufacturing facility in Holly Springs, North Carolina, is designed to expand production capacity for biologic medicines. In Canada, a federal investment of CAD 127 million in Aspect Biosystems and Providence Health Care is supporting bioprinted tissue therapeutics and advanced life sciences infrastructure, creating opportunities in regenerative medicine, tissue engineering, and cell therapies.

Asia Pacific is projected to be the fastest-growing region, registering a CAGR of 16.8% during the forecast period, showcasing the fastest-growing regional market. Japan has approved two induced pluripotent stem cell (iPSC)-based therapies, RiHEART and AMCHEPRY, for treating heart failure and Parkinson's disease, supporting regenerative medicine commercialization. China is strengthening its biomedical innovation ecosystem through a national pharmaceutical industry development plan that prioritizes biotechnology research, innovative drug development, and advanced manufacturing. In India, the Biopharma SHAKTI initiative, with a proposed outlay of ₹10,000 crore over five years, aims to strengthen biologics and biosimilar production, research infrastructure, and biotechnology innovation.

Europe is projected to register a CAGR of 12.3% during the forecast period. The region is strengthening its biologics and advanced therapy manufacturing infrastructure through investments in specialized production facilities. In the U.K., FUJIFILM Biotechnologies' approximately GBP 400 million investment in an expanded Teesside facility includes single-use bioreactors with a combined capacity of up to 19,000 litres. In Germany, Sartorius Stedim Biotech's investment of more than EUR 140 million in a new competence center in Freiburg is strengthening the supply of critical materials such as cytokines and growth factors for cell and gene therapy manufacturing.

Key Players Analysis

The biotechnology market is moderately fragmented, with multinational biotechnology companies, pharmaceutical manufacturers, biopharmaceutical developers, genetic engineering firms, and specialized life science technology providers. Leading companies compete through research and development capabilities, intellectual property portfolios, product innovation, clinical development expertise, regulatory compliance, manufacturing capacity, and global distribution networks. The five leading companies identified in the report's competitive landscape include:

• AstraZeneca PLC
• Gilead Sciences, Inc.
• Bristol Myers Squibb Company
• Pfizer Inc.
• Amgen Inc.

Conclusion

The biotechnology market is projected to record substantial growth through 2034, supported by advances in biopharmaceutical development, genetic engineering, regenerative medicine, and industrial biotechnology. North America holds the leading market position, while Asia Pacific is expected to record the fastest growth. DNA sequencing and human health currently dominate their respective segments, whereas nanobiotechnology and bioinformatics represent notable growth areas. Continued investment in precision fermentation, continuous bioprocessing, and advanced biological therapies will shape the industry's future.

About Us

Straits Research provides market intelligence, industry analysis, market forecasts, and competitive assessments across global industries. Its research helps organizations understand market dynamics, identify opportunities, and make informed strategic decisions.

Contact Us

Website: https://straitsresearch.com

Email: [email protected]

U.S.: +1 646 905 0080

India: +91 8087085354

U.K.: +44 203 695 0070